ofatumumab + dexamethasone + cisplatin + cytarabine

Ofatumumab + dexamethasone + cisplatin + cytarabine is a four-drug combination regimen used as second-line or salvage therapy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other aggressive B-cell lymphomas. This regimen is often termed "O-DHAP" and was evaluated as an alternative to rituximab in the standard R-DHAP regimen. Ofatumumab is a fully human anti-CD20 monoclonal antibody that targets B lymphocytes. Cisplatin and cytarabine are chemotherapeutic agents (platinum-based and antimetabolite, respectively), while dexamethasone is a glucocorticoid with both anti-inflammatory and cytotoxic antitumor actions. The mechanisms of action are complementary: ofatumumab mediates immune destruction of CD20-expressing B-cells; cisplatin induces DNA cross-linking leading to apoptosis; cytarabine inhibits DNA synthesis; dexamethasone promotes lymphocyte apoptosis and modulates immune response. This regimen is used in patients who are eligible for autologous stem cell transplantation and have failed prior therapies, especially those refractory to R-CHOP-like treatments[2][7][9].

Other names

ofatumumab + DHAPO-DHAPofatumumab + dexamethasone + cytarabine + cisplatin